Literature DB >> 24549480

[Current status of oral immunomodulatory and immunosuppressive agents].

S Meller1, A M Baran, S A Braun, N Klossowski, B Homey.   

Abstract

Various dermatological disorders require treatments with immunosuppressive or immunomodulatory agents. Nevertheless, several studies demonstrate low prescription rates for systemic treatments. This low usage may be a result of physicians' low levels of confidence in administering systemic treatments. However, immunosuppressive treatments represent safe options when potential side effects as well as pharmacological interactions are considered. This review overviews the most important oral immunosuppressive or immunomodulatory agents and summarizes their mode of actions, indications, and adverse effects. Biologics that require intravenous or subcutaneous application are not included, but novel and new agents likely to be released soon are considered.

Mesh:

Substances:

Year:  2014        PMID: 24549480     DOI: 10.1007/s00105-013-2652-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  34 in total

Review 1.  Hypersensitivity reactions to dapsone: a systematic review.

Authors:  Maria Lorenz; Gottfried Wozel; Jochen Schmitt
Journal:  Acta Derm Venereol       Date:  2012-03       Impact factor: 4.437

2.  New Glucocorticoids on the Horizon: Repress, Don't Activate!

Authors:  In-Ho Song; Ralf Gold; Rainer H Straub; Gerd-Rüdiger Burmester; Frank Buttgereit
Journal:  J Rheumatol       Date:  2005-06       Impact factor: 4.666

Review 3.  Optimised glucocorticoid therapy: the sharpening of an old spear.

Authors:  Frank Buttgereit; Gerd-Rüdiger Burmester; Brian J Lipworth
Journal:  Lancet       Date:  2005 Feb 26-Mar 4       Impact factor: 79.321

4.  Krüppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes.

Authors:  Florian Spörl; Sandra Korge; Karsten Jürchott; Minetta Wunderskirchner; Katja Schellenberg; Sven Heins; Aljona Specht; Claudia Stoll; Roman Klemz; Bert Maier; Horst Wenck; Annika Schrader; Dieter Kunz; Thomas Blatt; Achim Kramer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

Review 5.  Dimethylfumarate for psoriasis: more than a dietary curiosity.

Authors:  Ulrich Mrowietz; Khusru Asadullah
Journal:  Trends Mol Med       Date:  2005-01       Impact factor: 11.951

Review 6.  Janus kinase inhibitors in autoimmune diseases.

Authors:  John J O'Shea; Apostolos Kontzias; Kunihiro Yamaoka; Yoshiya Tanaka; Arian Laurence
Journal:  Ann Rheum Dis       Date:  2013-04       Impact factor: 19.103

7.  Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.

Authors:  A Nast; N Reytan; S Rosumeck; R Erdmann; B Rzany
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-06-23       Impact factor: 6.166

Review 8.  Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.

Authors:  Hakan M Gürcan; A Razzaque Ahmed
Journal:  Am J Clin Dermatol       Date:  2009       Impact factor: 7.403

9.  Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells.

Authors:  Kamran Ghoreschi; Jürgen Brück; Christina Kellerer; Caishu Deng; Haiyan Peng; Oliver Rothfuss; Rehana Z Hussain; Anne R Gocke; Annedore Respa; Ivana Glocova; Nadejda Valtcheva; Eva Alexander; Susanne Feil; Robert Feil; Klaus Schulze-Osthoff; Rudolf A Rupec; Amy E Lovett-Racke; Ralf Dringen; Michael K Racke; Martin Röcken
Journal:  J Exp Med       Date:  2011-10-10       Impact factor: 14.307

10.  A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Authors:  W C Ports; S Khan; S Lan; M Lamba; C Bolduc; R Bissonnette; K Papp
Journal:  Br J Dermatol       Date:  2013-07       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.